Clinical Trial Update: Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and preliminary efficacy of INCB050465 in combination with bendamustine and obinutuzumab in relapsed or refractory follicu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• INCB050465
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Incyte Corporation | Conditions: Lymphoma | Phase 1 | Status: COMPLETED